AJIC: American Journal of Infection Control
Volume 38, Issue 1 , Pages 44-49 , February 2010

Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus

  • Joseph Menzin, PhD

      Affiliations

    • Boston Health Economics, Inc., Waltham, MA
    • Corresponding Author InformationAddress correspondence to Joseph Menzin, PhD, Boston Health Economics, Inc., 20 Fox Road, Waltham, MA 02451.
    • ,
  • Jeno P. Marton, MD

      Affiliations

    • Pfizer Inc., New York, NY
    • ,
  • Juliana L. Meyers, MA

      Affiliations

    • Boston Health Economics, Inc., Waltham, MA
    • ,
  • Robyn T. Carson, MPH

      Affiliations

    • Pfizer Inc., New York, NY
    • ,
  • Constance D. Rothermel, PhD

      Affiliations

    • Pfizer Inc., New York, NY
    • ,
  • Mark Friedman, MD

      Affiliations

    • Boston Health Economics, Inc., Waltham, MA

References 

  1. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C, et al. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). Clin Infect Dis. 2007;45:1132–1140
  2. Division of Healthcare Quality Promotion . National center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–485
  3. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med. 2005;165:1756–1761
  4. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother. 1999;44(Suppl A):19–23
  5. Martone WJ, Nichols RL. Recognition, prevention, surveillance, and management of surgical site infections: introduction to the problem and symposium overview. Clin Infect Dis. 2001;33(Suppl 2):S67–S68
  6. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006;12:1715–1723
  7. Chambers HF. The changing epidemiology of Staphylococcus aureus?. Emerg Infect Dis. 2001;7:178–182
  8. Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis. 2003;45:287–293
  9. Ploy MC, Grelaud C, Martin C, De LL, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 1998;351:1212
  10. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs. 2003;63:1459–1480
  11. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, et al. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol. 1992;13:582–586
  12. Marton JP, Menzin J, Sussman M, Friedman M, Philburn RT, Rothermel CD. The clinical and economic burden of complicated skin and skin structure infections due to Staphylococcus aureus: findings from a national database. Value Health. 2007;10:A165–A166
  13. Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol. 2007;28:1290–1298
  14. Agency for Healthcare Research and Quality (AHRQ). HCUP comorbidity software v3.2. 1-31-2007. Available from: http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp#overview. Accessed July 15, 2007.
  15. US Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes. Consumer price indexes (CPI). 2006. Available from: http://www.bls.gov/cpi/home.htm. Accessed January 21, 2006.
  16. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother. 2004;38:1377–1382

 Supported by Pfizer, Inc.

 Conflicts of interest: Juliana Meyers and Joseph Menzin are employees of Boston Health Economics, Inc.; Mark Friedman is a consultant to Boston Health Economics, Inc; and Boston Health Economics, Inc., is a paid consultant to Pfizer in connection with the development of this manuscript.

PII: S0196-6553(09)00626-9

doi: 10.1016/j.ajic.2009.04.287

AJIC: American Journal of Infection Control
Volume 38, Issue 1 , Pages 44-49 , February 2010

Article Tools